FDA

Definium Therapeutics has announced the strong Phase 3 results of its single-dosed lysergide drug DT120 in treating adults with major depressive disorder. It met its main goal and all key secondary efficacy endpoints in the first trial of its kind.

We might be on the verge of a critical breakthrough treatment for pattern hair loss, with a novel slow-release oral drug meeting its significant endpoints in a Phase II/III trial of 519 patients. The next results are due later this year.

The US has broken a two-decade drought with the Food and Drug Administration adding bemotrizinol to the list of approved active ingredients that can be used in sunscreen, paving the way for more effective protection from ultraviolet radiation.

The US has its first and only oral COVID-19 post-exposure prophylaxis on its way, after a Phase III trial of the drug ensitrelvir met its goals needed for US Drug and Food Administration approval. It dramatically reduces spread from close contacts.

In a landmark shift in how mental health conditions are treated in the near future, the US Food and Drug Administration has approved the first at-home brain-stimulation device that can rapidly relieve moderate to severe depression symptoms.

Millions of Americans can now look forward to a better time traveling, with the US Food and Drug Administration approving a novel oral pill that helps prevent motion-induced vomiting – the first of its kind in more than 40 years.

The next transformative phase of weight-loss medication is upon us, with the US Food and Drug Administration (FDA) approving Novo Nordisk's highly anticipated oral GLP-1 drug – with a starting dose available in early January for US$149.

The US Food and Drug Administration (FDA) has approved the first intranasal diuretic for heart, liver and kidney disease patients, aiming to prevent a common and costly issue that results in more than a million hospitalizations each year.

The FDA has approved a new version of an Alzheimer’s disease drug that can be given as a quick at-home weekly injection, offering patients a more convenient option than lengthy infusion-center visits. It will be widely available from October 6, 2025.

The first aceclidine-based eye drop to improve near vision in adults with age-related presbyopia, which affects more than 100 million adults in the US alone, has been approved by the Food and Drug Administration and will be on sale by November.

The US Food and Drug Administration has instructed all GLP-1 drug-makers to update warning labels to include the risk of serious kidney injury that can result from dehydration. This comes after cases of acute kidney injury have required hemodialysis.

In a comprehensive new study looking at 39,763 different foods and drinks from the biggest 25 companies in the country, scientists discovered that almost 20% rely on synthetic food dyes to attract consumers. Now, the fight is on to ban them for good.